Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
New Molecule Therapy for Lung Cancer: MicroRNA
ijms-logo
Submit to IJMS Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

New Molecule Therapy for Lung Cancer: MicroRNA

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (20 February 2024) | Viewed by 1679

Special Issue Editors

Dr. Roberto Cuttano

E-Mail Website
Guest Editor
Unit of Cancer Biomarkers, ISBReMIT, Hospital Casa Sollievo della Sofferenza - IRCCS, San Giovanni Rotondo, FG, Italy
Interests: miRNA; biomarkers; molecular oncology; therapy resistance
Dr. Tommaso Colangelo

E-Mail Website1 Website2
Guest Editor
Cancer Biomarkers Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy
Interests: microRNA; cancer; bioinformatics; cancer biomarkers

Special Issue Information

Dear Colleagues,

Despite the recent advances in cancer treatment, lung cancer still remains the main cause of cancer-related deaths worldwide. Thus, there is a particular need for the development of new therapeutic strategies to improve the survival rates of lung cancer patients.

MicroRNAs are a type of small non-coding RNA that functions as important post-transcriptional regulators of gene expression and are involved in pivotal cellular processes. MiRNAs are profoundly dysregulated in several human cancers and are considered as ideal biomarker candidates due to their exceptional stability in harsh conditions. In addition, miRNAs are used to target several oncogenes or tumor suppressor genes, which contribute to cancer progression, and to modulate genes that mediate resistance to therapy. In line with this, several ongoing pre-clinical or clinical trials are evaluating miRNAs as potential biomarkers for response to therapy, as well as therapeutics to treat lung cancer. However, their transfer into clinical practice has been limited by several aspects, such as their complex mechanism of action, the lack of robust methodologies to investigate miRNA–target interaction and issues related to the safe and effective in vivo delivery of miRNA therapeutics.

In this special issue entitled “New Molecule Therapy for Lung Cancer: MicroRNA”, we are interested in recent studies that elucidate the role of miRNAs-based biomarkers and therapeutics as a new tool for lung cancer management.

Dr. Roberto Cuttano
Dr. Tommaso Colangelo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microRNA
  • lung
  • cancer
  • therapy
  • biomarker
  • resistance

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 4571 KiB  
Article
Stable Dual miR-143 and miR-506 Upregulation Inhibits Proliferation and Cell Cycle Progression
by Archana Shrestha, Behnaz Lahooti, A. K. M. Nawshad Hossian, Mahboubeh Madadi, Constantinos M. Mikelis and George Mattheolabakis
Int. J. Mol. Sci. 2024, 25(8), 4432; https://doi.org/10.3390/ijms25084432 - 17 Apr 2024
Viewed by 570
Abstract
The mainstays of lung cancer pathogenesis are cell cycle progression dysregulation, impaired apoptosis, and unregulated cell proliferation. While individual microRNA (miR) targeting or delivering is a promising approach that has been extensively studied, combination of miR targeting can enhance therapeutic efficacy and overcome [...] Read more.
The mainstays of lung cancer pathogenesis are cell cycle progression dysregulation, impaired apoptosis, and unregulated cell proliferation. While individual microRNA (miR) targeting or delivering is a promising approach that has been extensively studied, combination of miR targeting can enhance therapeutic efficacy and overcome limitations present in individual miR regulations. We previously reported on the use of a miR-143 and miR-506 combination via transient transfections against lung cancer. In this study, we evaluated the effect of miR-143 and miR-506 under stable deregulations in A549 lung cancer cells. We used lentiviral transductions to either up- or downregulate the two miRs individually or in combination. The cells were sorted and analyzed for miR deregulation via qPCR. We determined the miR deregulations’ effects on the cell cycle, cell proliferation, cancer cell morphology, and cell motility. Compared to the individual miR deregulations, the combined miR upregulation demonstrated a miR-expression-dependent G2 cell cycle arrest and a significant increase in the cell doubling time, whereas the miR-143/506 dual downregulation demonstrated increased cellular motility. Furthermore, the individual miR-143 and miR-506 up- and downregulations exhibited cellular responses lacking an apparent miR-expression-dependent response in the respective analyses. Our work here indicates that, unlike the individual miR upregulations, the combinatorial miR treatment remained advantageous, even under prolonged miR upregulation. Finally, our findings demonstrate potential advantages of miR combinations vs. individual miR treatments. Full article
(This article belongs to the Special Issue New Molecule Therapy for Lung Cancer: MicroRNA)
►▼ Show Figures

Figure 1

15 pages, 2394 KiB  
Article
Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma
by Mei-Chee Tai, Leonidas E. Bantis, Gargy Parhy, Taketo Kato, Ichidai Tanaka, Chi-Wan Chow, Junya Fujimoto, Carmen Behrens, Tetsunari Hase, Koji Kawaguchi, Johannes F. Fahrmann, Edwin J. Ostrin, Kohei Yokoi, Toyofumi F. Chen-Yoshikawa, Yoshinori Hasegawa, Samir M. Hanash, Ignacio I. Wistuba and Ayumu Taguchi
Int. J. Mol. Sci. 2024, 25(4), 2331; https://doi.org/10.3390/ijms25042331 - 16 Feb 2024
Viewed by 761
Abstract
Early-stage lung adenocarcinoma (LUAD) patients remain at substantial risk for recurrence and disease-related death, highlighting the unmet need of biomarkers for the assessment and identification of those in an early stage who would likely benefit from adjuvant chemotherapy. To identify circulating miRNAs useful [...] Read more.
Early-stage lung adenocarcinoma (LUAD) patients remain at substantial risk for recurrence and disease-related death, highlighting the unmet need of biomarkers for the assessment and identification of those in an early stage who would likely benefit from adjuvant chemotherapy. To identify circulating miRNAs useful for predicting recurrence in early-stage LUAD, we performed miRNA microarray analysis with pools of pretreatment plasma samples from patients with stage I LUAD who developed recurrence or remained recurrence-free during the follow-up period. Subsequent validation in 85 patients with stage I LUAD resulted in the development of a circulating miRNA panel comprising miR-23a-3p, miR-320c, and miR-125b-5p and yielding an area under the curve (AUC) of 0.776 in predicting recurrence. Furthermore, the three-miRNA panel yielded an AUC of 0.804, with a sensitivity of 45.8% at 95% specificity in the independent test set of 57 stage I and II LUAD patients. The miRNA panel score was a significant and independent factor for predicting disease-free survival (p < 0.001, hazard ratio [HR] = 1.64, 95% confidence interval [CI] = 1.51–4.22) and overall survival (p = 0.001, HR = 1.51, 95% CI = 1.17–1.94). This circulating miRNA panel is a useful noninvasive tool to stratify early-stage LUAD patients and determine an appropriate treatment plan with maximal efficacy. Full article
(This article belongs to the Special Issue New Molecule Therapy for Lung Cancer: MicroRNA)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop